Precigen, Inc.
PAPZIMEOS
Recurrent Respiratory Papillomatosis (RRP)
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on PAPZIMEOS for Recurrent Respiratory Papillomatosis (RRP) is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 14h ago
“The FDA has set a PDUFA action date of March 27, 2026.”